This is an early scientific progress update that does not alter the clinical or regulatory timeline. No catalyst for stock movement. Monitor for next clinical milestone or partnership announcement for EVX-V1, which is still in preclinical development and years from potential commercialization.
Price Chart
Executive Summary
Evaxion announced new preclinical data for its CMV vaccine program EVX-V1, presented at an industry conference. The data shows AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in mice, supporting the multi-component vaccine concept. This is an early-stage scientific update with no clinical data or regulatory milestone, and the stock has historically declined on similar neutral-content filings.
Key Facts
- New preclinical data for EVX-V1 presented at International Herpesvirus Workshop 2026 in Montreal
- Data show AI-discovered novel T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
- EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV antigens
- No licensed CMV vaccine currently exists; CMV treatment market valued at $474.6M in 2023, CAGR 6.6%
- Evaxion is a clinical-stage TechBio company with $26M market cap; no financial data or guidance provided in this filing
Financial Impact
No financial figures reported; preclinical data update with no revenue or cost implications
Risk Factors
- Preclinical data may not translate to human clinical results
- EVX-V1 remains in early development; no IND or Phase 1 start announced
- Evaxion's need for additional capital could lead to dilution before EVX-V1 reaches clinic
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004586 |
| Document: f6k_071026.htm | 0001171843-26-004586 |
| Document: 0001171843-26-004586-index-headers.html | 0001171843-26-004586 |
| Document: 0001171843-26-004586-index.html | 0001171843-26-004586 |
| Document: 0001171843-26-004586.txt | 0001171843-26-004586 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access